Evidence map›Paper›PMID 41308056›Full record

ReviewHormone research in paediatrics2025

EndoCompass Project: Research Roadmap for Adrenal and Cardiovascular Endocrinology.

Eystein S Husebye, Guillaume Assié, Nils Krone, John C Achermann, Barbara Altieri, Laurence Amar, Marta Araujo-Castro, Morris J Brown, Ruth T Casey, Hedi L Claahsen-van der Grinten and 15 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hormone research in paediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Eystein S HusebyeDepartment of Clinical Science, University of Bergen, Bergen, Norway, eystein.sverre.husebye@helse-bergen.no.
Guillaume AssiéInstitut Cochin, INSERM U1016, CNRS UMR8104, Paris, France.
Nils KroneDivision of Clinical Medicine, University of Sheffield, Sheffield, UK.
John C AchermannUCL Great Ormond Street Institute of Child Health, Genetics and Genomic Medicine, London, UK.
Barbara AltieriDivision of Endocrinology and Diabetes, Department of Internal Medicine I, Universitätsklinikum Würzburg, Würzburg, Germany.
Laurence AmarHopital Europeen Georges Pompidou - Hypertension Unit, Paris, France.
Marta Araujo-CastroHospital Universitario Ramon y Cajal, Endocrinology and Nutrition, Madrid, Spain.
Morris J BrownClinical Pharmacology and Precision Medicine, The William Harvey Research Institute, Faculty of Medicine and Dentistry, University of London, London, UK.
Ruth T CaseyDepartment of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
Hedi L Claahsen-van der GrintenDepartment of Paediatrics, Radboud University Medical Center, Amalia Children's Hospital, Nijmegen, The Netherlands.
Eleanor DaviesSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Jaap DeinumDepartment of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Christa E FlückDivision of Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Bern, University Hospital Inselspital, University of Bern, Bern, Switzerland.
Darko KastelanDepartment of Endocrinology, University Hospital Centre Zagreb, Zagreb, Croatia.
Matthias KroissDepartment of Internal Medicine IV, Ludwig-Maximilians Universität München, LMU University Hospital, Munich, Germany.
Paolo MulateroDivision of Internal Medicine and Hypertension, Department of Medical Sciences, University of Turin, Turin, Italy.
Saila LaaksoUniversity of Helsinki and Helsinki University Hospital - Children's Hospital, Helsinki, Finland.
Simon H PearceTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Martin ReinckeDepartment of Internal Medicine IV, Ludwig-Maximilians Universität München, LMU University Hospital, Munich, Germany.
Nicole ReischDepartment of Internal Medicine IV, Ludwig-Maximilians Universität München, LMU University Hospital, Munich, Germany.
Mercedes RobledoHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Cristina L RonchiDepartment of Metabolism and System Science, University of Birmingham, Birmingham, UK.
Dimitra A VassiliadiDepartment of Endocrinology and Metabolism, Evangelismos General Hospital, European Reference Network on Rare Endocrine Conditions (Endo-ERN), Athens, Greece.
Verena WiegeringDepartment of Pediatric, Hematology and Oncology, University Hospital of Würzburg, Würzburg, Germany.
Maria-Christina ZennaroInserm, PARCC, Université Paris Cité, Paris, France, maria-christina.zennaro@inserm.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndocrine science remains underrepresented in European Union research programmes despite the fundamental role of hormone health in human well-being. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding towards endocrinology. The EndoCompass project - a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology, aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges.

methodsResearch priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in adrenal endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups.

resultsFor adrenal disorders, research priorities span primary and secondary adrenal insufficiency, adrenal tumours, and endocrine hypertension. Key areas include development of biomarkers and replacement therapies, improved understanding of disease mechanisms, diagnostic procedure optimization, and establishment of pan-European registries. Special emphasis is placed on personalized treatment approaches.

conclusionsThe adrenal component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into adrenal disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of adrenal disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact on endocrine health.

Indexed as

Biomedical ResearchEndocrinologyAdrenal InsufficiencyChildDatabases, FactualHumansAdrenalAdrenal insufficiencyAdrenal tumoursCardiovascularEndoCompassEndocrine hypertensionFundingRoadmap

Identifiers

PMID41308056
PMCPMC12698127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.